trial

Staccato Loxapine in Agitated Patients With Schizophrenia

NCTId NCT00628589
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 344 (actual)
Sponsored by Alexza Pharmaceuticals, Inc.
Primary completion 2008-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
344 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-02
Primary completion
2008-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Inhaled Loxapine 5 mgInhaled Loxapine 10 mg

Sponsors

Alexza Pharmaceuticals, Inc.Lead Sponsor

Investigators

1
Robert S Fishman, MDStudy Director

Sites

1 total
Atlanta, United States

Linked catalysts

1
Staccato Loxapine in Agitated Patients With Schizophrenia — primary completion2008-05

Facts & assertions

4 sourced
Enrollment
344
Phase
PHASE3
Primary Completion Date
2008-05
Status
COMPLETED
relationships
The graph out of here
drug
Inhaled Loxapine 5 mg
drug
Inhaled Loxapine 10 mg
drug
lead_sponsor
Alexza Pharmaceuticals, Inc.
company
indication
Psychomotor Agitation
indication
Schizophrenia
indication
Patients With Schizophrenia and Acute Agitation
indication
investigator
Robert S Fishman, MD
person